Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Return on Sales (2024 - 2025)

Historic Return on Sales for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Q3 2025 value amounting to 2.12%.

  • Monte Rosa Therapeutics' Return on Sales rose 4700.0% to 2.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.12%, marking a year-over-year increase of 80900.0%. This contributed to the annual value of 0.96% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Return on Sales is 2.12%, which was up 4700.0% from 0.53% recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Return on Sales high stood at 0.55% for Q1 2025, and its period low was 30.06% during Q1 2024.